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Abstract 
There is growing evidence and concern documenting the risks of antipsychotic use, and 
psychotropic medication burden in general, for older adults with behavioral and psychological 
symptoms of dementia (BPSD). Yet nearly 25 percent of all long term care residents take 
antipsychotics for behavioral disturbances associated with dementia as “off-label” use, despite 
their modest efficacy and FDA black box warnings (CMS, 2013). Expert consensus calls for 
non-pharmacological strategies as the first line treatment, yet some patients with BPSD may 
require a combination of non-pharmacological interventions and pharmacological treatments for 
symptom reduction (AGS, 2011). The relief of debilitating symptoms aims to improve quality of 
life, and reduce patient and caregiver distress. The purpose of this quality improvement project 
was to implement use of an evidence-based psychotropic risk assessment checklist, that 
integrates palliative medicine with the dementia disease trajectory, to guide treatment decisions 
for psychotropic risk reduction, and improve the documentation of outcome measures and 
person-centered care. The checklist was initially used in four separate skilled nursing facilities 
over a period of eight weeks. The adoption of the checklist to change practice patterns, and 
influence the prescribing culture in the nursing homes, was founded on Roger’s Diffusion of 
Innovation theory (Rogers, 2003). Evaluation methods included qualitative impact results from 
the interdisciplinary team, and chart review for increased utilization and documentation of non-
pharmacological interventions, and shared-decision making on goals of care. Additional future 
outcomes may include, reduced psychotropic use for public reporting with national 
benchmarking, and improved survey results from oversight and regulatory organizations. The 
checklist is simple yet comprehensive, has good feasibility for long-term care, and is projected to 
expand to the electronic health record for clinician access and utilization in diverse settings. 
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A Novel Psychotropic Risk Assessment To Enhance Medical Management Of Patients With 
Behavioral And Psychological Symptoms Of Dementia 
Introduction 
Background and significance 
There is a mounting body of evidence documenting the risks of antipsychotic use for the 
older adult with behavioral and psychological symptoms of dementia (BPSD). At the same time, 
the prevalence of these medications in U.S. nursing homes is still about 24 percent (CMS, 2013). 
Geriatric agitation is seen in about 50-60 % of patients with advanced dementia and as much as 
80 % in patients with dementia in nursing homes (Castle, Hanlon, & Handler, 2009; Huybrechts, 
et al., 2012; Kamble, Chen, Sherer, & Aparasu, 2009; Lester, Kohen, Stefanacci, & Feuerman, 
2010). The symptoms of BPSD include agitation, aggression, anxiety, hallucinations, delusions, 
and depression. The most common antecedents to institutionalization are wandering, agitation, 
incontinence, and psychosis (Ballard, Waite, & Birks, 2006; Hersch & Falzgraf, 2007; Liperoti, 
Pedrone, & Consonello, 2008). Expert consensus recommendations call for non-pharmacological 
strategies to be used as the first line treatment, yet some patients with BPSD may require a 
combination of non-pharmacological interventions and pharmacological treatments for symptom 
reduction (AGS, 2011; O’Neil, Freeman, Christensen, Addleman, & Kansagara, 2011). These 
symptoms pose a significant physical and emotional burden on patients and families, and often 
precipitate nursing home admissions due to caregiver burnout and fatigue (AGS, 2011; Kamble 
et al., 2009; Lester, et al., 2011).  
Management of these difficult behaviors aim to reduce risk of injury, and improve quality 
of life (QoL), (Lyketsos, et al., 2006; Lyketsos, 2007; Mohamed et al., 2012). Some evidence 
suggests that psychosis and agitation in patients with dementia not only decrease QoL (Liperoti, 
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et al., 2008; Ryu, Ha, Park, Yu, Livingston, 2011; Wetzels, Zuidema, Jonghe, Verhey, 
Koopmans, 2010), but may also predict a worse prognosis (Banerjee, et al., 2006; Hersch, & 
Falzgraf, 2007; Matsui, et al., 2006; Tun, Murman, Long, Colenda, & Von Eye, 2007).  Tun, et 
al., (2007), found the presence of BPSD correlated negatively with survival rates over a three 
year period, and other studies have reported psychosis in Alzheimer’s disease is associated with 
increased mortality and accelerated cognitive decline (Gauthier, et al., 2010; Salzman, et al., 
2008).  
There is a paradigm shift emerging in healthcare, gradually spreading to long-term care 
as well, that supports a movement away from the medical model or a clinician-disease ethos, to 
person-centered care (Kolanowski, & Van Haitsma, 2013). The seminal report, Crossing the 
Quality Chasm from the Institute of Medicine (IOM) in 2001, described healthcare in the United 
States as “impersonal and fragmented”. In an effort to achieve optimal healthcare and well being, 
care must address the whole person, including the bio-psycho-social-spiritual aspects of being. 
The term person-centered has become accepted as the gold standard, and refocuses care to 
meeting goals and shared decision-making. Person-centered values and practices emerged from 
humanistic psychology and the foundational work of Carl Rogers and Abraham Maslow. Person-
centered care, as taken from the “Toolkit: Promoting Positive Behavioral Health, Person-
Centered Care: An Overview” (Kolanowski, & Van Haitsma, 2013)  
• Focuses care on choices, goals for care, and personal preferences. 
• Emphasizes and recognizes the individual person’s self-determination, unique 
set of values, perspectives, histories and interests (Koren, 2010). 
• Promotes a life affirming, satisfying humane, and meaningful experience     
(para. 2).  
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Local problem 
The treatment of BPSD in advanced dementia is challenging, because these patients are 
often frail, and have numerous comorbid conditions that may affect the disease trajectory, (see 
Figure 1 for dementia disease trajectory). Yet the relief of these debilitating symptoms may 
improve the QoL, and reduce patient and family distress (Hersch & Falzgraft, 2007; Liperoti, et 
al., 2008; Wetzels, et al., 2010). As patients move along the dementia disease trajectory and 
across different settings of care, a palliative care approach with comfort-focused strategies may 
assist clinicians with treatment decisions to improve quality outcomes for older adults with late 
life BPSD, and decrease the burden of disease.  
Person-centered palliative care can be integrated into dementia care as a new clinical 
pathway to restructure care services that incorporate the expertise of the IDT to work 
collaboratively to meet the needs of the patient. Utilizing the knowledge from pharmacists, 
dieticians, gero-psych practitioners, therapists, and nursing will strengthen the care delivery 
system.  Discussions with family members or the proxy to establish realistic goals of care with 
comfort care as a priority, is a process of shared decision-making, that is often undocumented, or 
not well established.   
After a complete medical evaluation, and if a substantial trial of non-pharmacological 
interventions have failed to ameliorate the patient’s symptoms, or if the symptoms of distress 
persist or escalate, the decision to start antipsychotic medication at low doses may be inevitable 
for some patients. Other psychotropic medications with a safer risk profile may be considered 
first if appropriate, (e.g. antidepressants, cholinesterase inhibitors, and mood stabilizers), 
depending on the target symptoms of most concern (Hersch, & Falzgraft, 2007). The medical 
evaluation of patients with BPSD requires a thorough and systematic approach with critical 
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thinking that is often chaotic or undocumented. The application of clinical guidelines and best 
practice have been lacking in long-term care. Increased knowledge of geriatric pharmacology is 
an ongoing need for nursing home clinicians.  
The medical management of patients with BPSD is complex, and requires experienced 
clinicians and professionals on the interdisciplinary team (IDT), and a referral to a behavior 
specialist or a psychiatric nurse working collaboratively with a psychiatrist, for a gero-
psychiatric evaluation may be beneficial. Nursing home clinicians are challenged by healthcare 
systems that have limited resources and staff with high rates of turnover. Advanced training in 
dementia care with an emphasis on non-pharmacological approaches is needed (Kolanowski, & 
Van Haitsma, 2013).  
The recommended maximum doses of antipsychotics for elderly patients with dementia 
based on examination of therapeutic and adverse effects are: risperidone 1.5 mg/day; olanzapine 
10 mg/day; quetiapine 200 mg/day; and aripiprazole 12 mg/day (Jeste et al., 2008). Potential side 
effects from antipsychotics include sedation, tardive dyskinesia, gait disturbances, falls, 
anticholinergic side effects, extrapyramidal symptoms, orthostatic hypotension, QT interval 
prolongation, cerebrovascular events, and increased mortality (Hersch, & Falzgraft, 2007).   
Antipsychotic medications require a careful consent process, and discussion with the 
patient or their surrogate decision maker, and documented in the medical record (AGS, 2011). 
Efforts should be made to design and implement improved consent processes with shared 
decision-making in long-term care. Disclosure of potential benefits and risks of all psychotropic 
medications is required. Nursing home clinicians must consider complex risk and quality 
concerns with multiple sources of information, but the process of critical thinking and analysis is 
often obscure, undocumented, or unavailable to the IDT.  
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Although some states restrict advance practice nurses (APNs) from prescribing 
antipsychotics in nursing home settings, they are often responsible for the clinical oversight of 
patients with BPSD, and need to be aware of antipsychotic safety concerns. Close monitoring for 
side effects by APNs and direct care staff, is important to evaluate treatment response, with an 
effort to keep the dose low, and begin dose reduction when possible. See the case presentation 
attached, demonstrating the role of APNs working collaboratively with IDT members to manage 
patients with BPSD. The case presentation also illustrates how utility of the Psychotropic Risk 
Assessment Tool and a palliative care approach informs clinical decision-making for an older 
adult with BPSD in a nursing home setting, and improves his quality of life.  
An important source of information for clinicians on prescribing guidelines for 
antipsychotic medications is the American Geriatrics Society 2012 Updated Beers Criteria for 
Potentially Inappropriate Medication Use in Older Adults (AGS, 2012). This source gives strong 
evidence-based recommendations to avoid antipsychotic medications in patients with dementia 
and cognitive impairment, and specifies these medications should not be used for the behavioral 
problems of dementia, unless non-pharmacological options have failed, or it the patient is a 
threat to self or others. However, the AGS 2012 Updated Beers Criteria also lists medications 
that may be used with caution in older adults, whereby, antipsychotics in this category are 
associated with more risks than benefits, but may be considered appropriate in certain 
circumstances, or with individuals near the end of life (AGS, 2012). The full document together 
with accompanying resources can be accessed online at www.americangeriatrics.org. 
Intended improvement 
Clinicians may be prompted by the IDT or regulatory organizations, to provide a 
statement of benefit/risk, to justify extended therapy with psychotropic medications, but they 
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lack tools and guidelines to provide these critical appraisals. The purpose of this quality 
improvement project was to compile evidence on psychotropic medications and dementia, 
implement use of an evidence-based psychotropic risk assessment checklist, and evaluate the 
benefits of this checklist at area skilled nursing facilities. The psychotropic risk assessment 
checklist brings previously developed instruments together into an easy to use checklist that is 
incorporated into the medical record. Clinicians and IDT members may use the checklist to 
implement and evaluate the effectiveness of non-pharmacological and pharmacological 
treatments, to enhance the appropriate use of psychotropic medications for nursing home 
residents with BPSD, and improve documentation.  
Review of the evidence 
Despite consensus recommendations that non-pharmacological interventions are the first-
line treatment (Azermai, et al., 2011; Gauthier, et al., 2010; Salzman, et al., 2008), there are few 
proven, effective non-pharmacological interventions for the persistent and problematic behaviors 
of advanced dementia, and severe geriatric agitation (Buhr, & White, 2006; Huybrechts, et al., 
2012; O’Neil, et al., 2011; Sink, Holden, & Yaffe, 2005). Livingston, Johnson, Katona, Paton, & 
Lyketsos (2007) found in a systematic review, that some behavior management therapies, 
caregiver and staff education, and possibly cognitive stimulation appear to have lasting 
effectiveness for the management of BPSD, however due to lack of high quality, well-designed 
or significantly powered research, the conclusions are limited. Kuerno, et al., (2008) reported in 
a systematic review of the literature, behavioral and pain management, environmental 
management, caregiving training, increasing pleasant events and lowering stress, are moderately 
efficacious in patients with mild to moderate dementia, but it remains unclear whether these 
strategies are effective in the later stages of the disease.  
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A comprehensive evidence-based synthesis of non-pharmacological approaches for 
BPSD was conducted by O’Neil, Freeman, Christensen, Addleman, & Kansagara (2011) at the 
Portland VA Medical Center, and funded by the Department of Veteran’s Affairs. It was titled, A 
Systematic Evidence Review of Non-pharmacological Interventions for Behavioral Symptoms of 
Dementia (June, 2011). O’Neil and colleagues developed this evidence-based synthesis program 
in order to develop best practice guidelines on clinical topics relevant to veterans in order to fill 
the gaps in our current knowledge of effective interventions for the treatment of BPSD. They 
searched MEDLINE, Cochrane Database of Systematic Reviews and Cochrane Database of 
Reviews of Effects through 2009 for systematic reviews related to dementia. Based on 21 good 
quality systematic reviews of a single non-pharmacological interventions, and seven good quality 
systematic reviews of comparisons of multiple interventions, they reported a few promising 
results with stimulation/sensory approaches (e.g. acupuncture, aromatherapy, light therapy, 
massage, music, Snoezelen Multisensory Stimulation Therapy, or TENS-Transcutaneous 
Electrical Nerve Stimulation). These interventions may be valid, but there were no head-to-head 
comparisons and the evidence was inconsistent. There were a few behavior techniques that 
showed some promise, but need additional validation and replication of results. These included, 
providing a calm predictable schedule, identifying and avoiding situations that agitate the patient, 
and redirecting and refocusing the patient. Behavioral techniques are primarily focused on 
caregiver training and support. They found some positive effects of exercise on sleep, and 
physical health. However, potential harms of exercise in older adults, such as increased risk of 
falls or physical injuries, and have not been well studied in older adult populations. Lastly, this 
comprehensive report proposed that non-pharmacological interventions may have potentially 
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fewer and less severe harms versus pharmacological interventions for BPSD, but they cannot 
recommend any, for lack of evidence.  
In a recent systematic review performed by Seitz, Brisbin, & Herrmann, (2012) 
investigating the efficacy and feasibility of non-pharmacological interventions for BPSD in long-
term care settings, they reported some evidence that, effectiveness of non-pharmacological 
interventions improve if they are consistently implemented over time. Seitz and colleagues 
concluded that research in this area, that has rigorously tested non-pharmacological interventions 
on older adults with BPSD, has been limited by small sample sizes, and the use of research teams 
to implement interventions rather than the nursing home staff. 
National consensus guidelines supported by multiple professional associations, call for an 
increased emphasis of non-pharmacological interventions, as the first line treatment for BPSD in 
long-term care settings. Recently, at the Gerontological Advanced Practice Nurses Association 
(GAPNA) annual meeting September 18-21, 2013, there was a panel discussion entitled, 
Antipsychotics and CMS Behavioral Health Initiative. A Toolkit was presented by Ann Marie 
Kolanowski, PhD, RN, to improve behavioral health in nursing homes, and was funded by the 
Commonwealth Foundation (Kolanowski & Van Haitsma, 2013). The purpose of the Toolkit was 
to compile resources and evidence-based recommendations with regard to alternative approaches 
to manage the challenging behaviors of BPSD. Dr. Kolanowski acknowledged, that the Toolkit: 
Promoting Positive Behavioral Health, was developed to address concerns that a void in care 
may be evident if psychotropic drug reduction is not supplemented by alternative approaches to 
problematic behaviors. In addition, there were long-term care administrative concerns, that a 
major barrier to implementing non-pharmacological interventions in these settings is a lack of 
education for long-term care providers. More education and training is needed to update 
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clinicians, nursing, and direct-care staff with skills and competencies. The toolkit and additional 
information is available for review and use at www.nursing.psu.edu/Hartford/toolkit. For a 
complete list of non-pharmacological approaches for treating BPSD recommended in the 
Toolkit, see Tables 1 and 2. On the Toolkit website, there are multiple 3-minute evidence-based 
coaching videos, to demonstrate how to engage residents who are exhibiting challenging 
behaviors during activities of daily living, and strategies to ameliorate agitation.  
The Toolkit provides current evidenced-based information that will help long-term care 
staff to understand the behaviors of BPSD, and provides information on clinical decision support 
approaches, and practical guidance for health care providers. Addressing the challenges that 
long-term care staff encounter when responding to the difficult behaviors of patients with BPSD 
in a resource-challenged environment, experts are increasingly emphasizing the need to identify 
non-pharmacological approaches that are feasible and efficacious (Kolanowski & Van Haitsma, 
2013). Resource challenges faced by nursing home health care providers include, limited access 
to staff with advanced training in dementia care, limited resources, and high rates of turnover. 
Kolanowski recommends the Toolkit as a guide to assist nursing homes to identify the “optimal 
evidence-feasibility fit” for their residents and facility. Feasibility was defined using Seitz and 
colleagues guidelines: high feasibility approaches require fewer resources, less cost of supplies, 
less complexity of the activity, minimal staff training, less need for additional personnel and less 
specialized personnel (Seitz, et al., 2012).      
To date, there are no Federal Drug Administration (FDA) approved medications for 
BPSD and the off-label prescribing of antipsychotics has been a growing concern to clinicians, 
patients, families, policy-makers, state and federal agencies and consumer groups. In 2005 the 
FDA issued a black box warning when atypical antipsychotics were associated with a 60 percent 
A NOVEL PSYCHOTROPIC RISK ASSESSMENT TO ENHANCE 12 
 
increased risk of death compared with placebo in randomized controlled trials among older adult 
patients with dementia (Schneider, Dagerman, & Insel, 2005).  Later in 2008, a black box 
warning was issued for the conventional antipsychotics as well (Huybrechts, et al., 2012). Since 
then, the prevalence of antipsychotics for the treatment of BPSD in U.S. nursing homes still 
ranges from 15-33 percent (Kamble, Chen, Sherer, & Aparasu, 2009; Lester, et al., 2011).  
A recent five-year retrospective study conducted by Rossom and colleagues, (2010) using 
U. S. Veterans Administration data from more than 89,000 veterans did not find an increased risk 
of death in veterans with dementia who were prescribed lower doses of olanzapine (<2.5 mg/d), 
quetiapine (<50 mg/d), or risperidone (<1 mg/d). However, at higher doses, these atypical 
antipsychotics (excluding quetiapine) were associated with an increased risk of death. All doses 
of haloperidol, a conventional antipsychotic, were associated with increased mortality. 
The mechanism(s) for increased mortality associated with antipsychotic use is still not 
well understood, and needs further research and analysis (AGS, 2011). One study that examined 
mortality risk, was a large epidemiological five-year retrospective nested case-control study of 
primary care patients in the United Kingdom (Parker, et al., 2010). They found that there was a 
32% greater risk for venous thromboembolism (VTE) in those prescribed antipsychotics in the 
previous 24 months versus non-antipsychotic users. The risk was greater for new users and those 
who were prescribed atypical antipsychotics. The study examined risk stratification by type of 
antipsychotic drug, potency and dose, and adjusted for comorbidity and concomitant drug 
exposure. The sample was (N=25,532) with a total of 89,491 matched healthy controls. The 
median age for all participants was 67 years. The researchers concluded more evidence is needed 
to understand the mechanisms for adverse events from antipsychotic therapy leading to 
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mortality, to allow risk profiling of patients, and eventually lead to approaches to minimize risk 
in those patients who otherwise may need and benefit from these medications (AGS, 2011).  
Data for antipsychotic utilization in U.S. nursing homes from 1996 through 2006, 
demonstrates that antipsychotic use increased from 16.4% to 25.9% respectively, despite the 
FDA black box warnings. A study conducted by Lester, Kohen, Stefanacci, & Feuerman (2011) 
using a nationwide survey to assess changes in antipsychotic utilization patterns since the black 
box warnings were imposed, found no decrease in their use, but noted a large number of U.S. 
nursing home facilities had implemented policies for informed consent on the use of these 
medications. 
Current literature and expert consensus supports gradual dose reductions and short-term 
use of antipsychotics for BPSD, however a recent RCT with high-grade (Level 2) evidence, 
conducted by Devanand, et al., (2012) has relevance to clinical practice, and may influence 
treatment decisions for dose reduction or discontinuance of antipsychotic medications. These 
researchers found in patients with Alzheimer’s disease who had psychosis or agitation-
aggression, and had responded to risperidone for 4 to 8 months, had an increased risk of relapse 
of symptoms once risperidone was discontinued, over the group that received placebo. A total of 
110 patients met criteria for randomization, and were randomly assigned to one of three 
regimens: continued risperidone (mean dose 0.97 mg daily) for 32 weeks (group 1), risperidone 
therapy for 16 weeks followed by placebo for 16 weeks (group 2), or placebo for 32 weeks 
(group 3). In the first 16 weeks after randomization, the rate of relapse was higher in the group 
that received placebo than in the groups that received risperdone (60% [24 of 40 patients in 
group 3] vs. 33% [23 of 70 in groups 1 and 2]; P=0.004; hazard ratio with placebo, 1.94; 95% 
confidence interval [CI], 1.09 to 3.45; P=0.02). During the next 16 weeks, the rate of relapse was 
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higher in the group that was switched from risperidone to placebo than in the group that 
continued to receive risperidone (48% [13 of 27 patients in group 2] vs. 15% [20 of 13 in group 
1]; P=0.02; hazard ratio, 4.88; 95% CI, 1.08 to 21.98; P=0.02). The findings suggest patients 
with psychosis or agitation-aggression, who had a sustained response to antipsychotic 
medications for 4 to 8 months, had a significantly increased risk of relapse for at least 4 months 
after discontinuation, and this finding should be weighed against the risk of adverse effects with 
continued antipsychotic treatment (Devarnand et al., 2012).  
Centers for Medicare and Medicaid Services (CMS) is concerned about the high off-label 
use of antipsychotics in nursing homes and sponsored an educational event in March 29, 2012 
entitled, Launch of the Initiative to Improve Behavioral Health and Reduce the Use of 
Antipsychotic Medications in Nursing Home Residents. This program showcased a national 
movement to increase awareness about the high prevalence of off-label use of antipsychotic 
medications, in nursing homes as a quality improvement initiative. This initiative set a modest 
goal to reduce antipsychotic use by 15 percent by the end of 2012. Centers for Medicare and 
Medicaid Services extended partnership with federal and state agencies, nursing homes 
nationally, advocacy groups and health care professionals to ensure appropriate use of 
antipsychotics with dementia care.  
Centers for Medicare and Medicaid Services has emphasized the strategies of partnership 
and increased education, transparency and awareness, although some believe more regulation 
and enforcement with penalties is needed to ensure appropriate use of antipsychotic medications 
(Senate Special Committee, CMS, 2012). Nursing homes are required to post their rates of 
antipsychotic utilization on a CMS website, Nursing Home Compare, which began in July, 2012 
for increased transparency, national benchmarking and quality measures. Centers of Medicare 
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and Medicaid Services has declared a higher goal in 2013, by reducing inappropriate prescribing 
of antipsychotics in nursing homes by 40 percent (CMS, 2013).  
In May, 2011, the high cost of antipsychotic drugs for nursing home residents was 
reported by the Department of Health and Human Service, Office of Inspector General (OIG) to 
be $116 million for a six-month period, January 1-June 30, 2007. This report from OIG 
addressed the utilization of atypical antipsychotics, including 1) 14% of elderly nursing home 
residents had Medicare claims for atypical antipsychotic drugs; 2) 83% of Medicare claims for 
atypical antipsychotics were for off-label conditions and 88% of Medicare claims were 
associated with the condition specified in the FDA black box warnings; 3) 51% of Medicare 
atypical antipsychotic drug claims for elderly nursing home residents did not comply with 
Medicare’s reimbursement criteria, amounting to $116 million in claims; and 4) 22% of the 
atypical antipsychotic drugs claimed through Medicare were not administered in accordance with 
the CMS standards regarding unnecessary drug use in nursing homes (OIG, 2011).  
Centers for Medicare and Medicaid Services objects to the high cost of antipsychotic 
medications for Medicare beneficiaries primarily because Medicare guidelines do not allow for 
off-label prescription reimbursements, in addition to the significant health risks, with imposed 
black box warnings for older adults with BPSD (Edelman, 2012). Data from CMS from 2010, 
demonstrates more than 17 percent of nursing home residents had daily doses exceeding the 
recommended levels, and 40 percent of nursing home residents with dementia were receiving 
antipsychotic medications even though there was no documented diagnosis of psychosis, 
according to CMS Chief Medical Officer and Director of Clinical Standards and Quality, Patrick 
Conway MD (CMS Press Release, 2012). 
A NOVEL PSYCHOTROPIC RISK ASSESSMENT TO ENHANCE 16 
 
The Centers of Medicare and Medicaid Services acknowledges that there are clinical 
indications for the use of antipsychotics and other psychotropic medications, in some older adults 
with BPSD (CMS.gov, 2013). They have updated the training of state surveyors, from the 
Medicare Learning Network, to evaluate the process of care when antipsychotic medications are 
used in long-term care facilities by looking for 1) person-centered care based on individualized 
needs, 2) documentation of the evaluation of new or worsening condition and target symptoms 
warranting antipsychotic drug use, 3) evidence of critical thinking related to antipsychotic drug 
use, 4) monitoring for potential side effects, 5) engagement of the resident/family or 
representative in decision making, and 6) quarterly documentation for gradual dose reduction to 
support continued use.   
Little is known about the prevalence and treatment of BPSD near the end of life 
(Banerjee, et al., 2006; Kverno, Rabins, Hicks, Black, 2008). Most research has focused on the 
mild to moderate stages of dementia. Still, there is limited evidence on available therapeutic 
strategies for late stage dementia and current recommendations are mainly from expert consensus 
(Alexopoulos, et al., 2005). Banerjee, et al., (2009) report in a systematic review of English 
papers up to October 2007, we know almost nothing about the natural history of QoL in patients 
with dementia or what interventions improve or worsen QoL.  Additionally, most evidence-based 
clinical guidelines are based on the management of a single condition, whereas many older 
adults have multiple comorbidities (Levenson, & Morley, 2007). Some symptoms such as 
agitation and aggression tend to worsen as the dementia becomes more advanced, (Lyketsos, et 
al., 2000), yet other patients may experience a decline in agitation as they approach the end of 
life.  
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Lawton (1991) provided a broad conceptual framework for QoL that laid a foundation to 
guide research in older adult populations. He identified four domains of importance: behavioral 
competence, the objective environment, psychological well-being, and perceived QoL. Each of 
these domains is highly relevant to evaluate QoL in older adults with cognitive impairment 
(Logsdon, et al., 2002). 
Quality of life measures for older adults with dementia are still emerging, however over 
the last decade, there have been important strides in contributing new knowledge to what we 
know about the long debilitating illness of Alzheimer’s disease (Crespo, Hornillos, & Bernaldo 
de Quiros, 2013). Quality of life measures for patients with dementia are utilized to evaluate the 
efficacy of interventions (e.g. behavioral interventions, drug treatments, or environmental 
modifications), (Black, Rabins, & Kasper, 2009). Additionally, QoL measures guide clinical 
decision-making and end-of-life (EOL) care, support decisions to initiate or discontinue 
treatments, and informs payors and policy-makers which treatment alternatives are most cost-
effective (Black, et al., 2009).  
Researchers interested in long-term care quality, have begun to shift their focus from how 
care is delivered or process of care, to how care affects residents, or outcomes of care (Slone, et 
al., 2005). Although defining and measuring QoL with persons who have dementia is complex, 
and a “gold standard” instrument does not exist, the current literature supports a combination of 
methods and sources to provide the most useful information on QoL (Slone, et al, 2005; Selai, & 
Trimble, 1999).  
Patients with dementia have increasing difficulty articulating their symptoms as the 
disease progresses. When patients with dementia loose their ability to participate in evaluating 
their self-perceived QoL, researchers and clinicians rely on information from proxies, or a close 
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observer (e.g., nurses, or caregivers), (Slone, et al., 2005). It is generally accepted that patients 
with severe cognitive impairment, and a Mini-Mental State Examination (MMSE) score below 
10 are unable to give reliable answers to questions for a number of reasons, (e.g., lack of 
memory, inability to concentrate, loss of words or language skills, or lack of awareness of their 
impairments and disabilities), (Slone, et al., 2005). A MMSE score below 10 has become the 
cutoff for “interviewability” (Mozley, et al, 1999; Naglie, et al, 2011).  
Current evidence suggests there is poor correlation with the patient’s own self-report, and 
the reports of proxies or staff (Logsdon, Gibbons, McCurry, & Teri, 2002; Slone, et al., 2005). 
However, it has been interpreted that patient and proxy report may represent valid but different 
perspectives on QoL (Ready, Ott, & Grace, 2004). Multiple sources of information may be 
necessary to better understand QoL in persons with dementia.  
Crespo, Hornillos and Bernaldo de Quiros (2013) found in a small cross-sectional study, 
(n=102 residents, 184 relatives, and 197 staff) that QoL of residents in nursing homes with 
dementia were correlated primarily with their emotional state (depression level), while proxies 
perceptions (both family and staff) were mainly associated with the resident’s functional ability 
in activities of daily living, and therefore perspectives of residents with dementia and proxies 
were not congruent. An additional finding in this study that adds evidence to support the current 
literature, was managing depression is an important intervention for impacting QoL for persons 
with dementia (Crespo, et al., 2013; Naglie, et al., 2011). 
Naglie, et al. (2011) conducted a Canadian cross-sectional study, (n=370) to discover 
whether core symptoms of Alzheimer’s disease (AD) consistently predict patient self-rated QoL 
as assessed by a variety of QoL instruments. They interviewed patients with AD in nursing 
homes, rated their QoL, and tested for cognition, function, behavioral and psychological 
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symptoms, and depression. They found self-rated symptoms of depression were a consistent 
independent predictor of patient-rated QoL across diverse QoL measures. These findings are 
clinically relevant, and support the current evidence in the importance of identifying and treating 
depression in patients with AD.   
Cordner, Blass, Rabins, & Black (2010) found in a cross-sectional study of advanced 
dementia nursing home residents, that QoL can be improved in this population by appropriate 
assessment of pain, and effective management of behavior problems. An additional outcome was 
support for the Alzheimer’s Disease Related QoL scale (ADRQL) administered to nursing home 
residents, surrogate decision-makers, and nursing home staff. They found the ADRQL is a valid 
indicator of QoL in nursing home populations with advanced dementia, yielding clinically 
relevant information with important implications for practice, primarily attention to pain and 
behavior problems.  
Over the past decade, there have been a variety of scales developed to measure QoL for 
persons with dementia. They range from single component measures to some that capture 
multiple domains. Sloan et al., (2005) sought to compare existing instruments for interrater 
reliability, internal consistency, and greater understanding of how resident measures correlate 
with proxy and staff measures. Two of these instruments have particular applicability and utility 
for nursing home settings and for populations of persons with advanced dementia. The Quality of 
Life in Alzheimer’s Disease (QOL-AD) scale; (Logsdon et al., 2000), has 13 items rated on a 4-
point scale (1 = poor, and 4 = excellent) yielding a summative score ranging from 15 to 60. The 
QOL-AD has one version designed for a person with AD, and one version designed for 
administration to a caregiver. The reported coefficient alpha for the patient version is 0.87 
(Logsdon et al., 2000). The other instrument of interest, and previously mentioned, is the 
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ADRQL (Rabins, & Steele, 1996). This instrument of 47 items is completed by a caregiver and 
describes behaviors that are judged by family caregivers and professionals to be important in the 
evaluation of health-related QoL in AD. The following 5 domains are measured: social 
interaction, awareness of self, feelings and mood, enjoyment of activities, and response to 
surroundings. Summary scores are added for each domain and for global quality of life, and 
range from 0 (lowest quality) to 100 (highest quality). The internal reliability of this scale is 
reported to range between 0.77 and 0.91 (Lyketsos et al., 2003).  
Other instruments used in addition to the QOL-AD and the ADRQL, to capture 
measurements of cognition, depression, pain, and agitation are likely to provide a comprehensive 
and complete picture of QoL for advanced dementia residents in nursing homes. The Geriatric 
Depression Scale (GDS) is a 30-item scale to rate the patient’s depressive symptoms, with scores 
greater than 10 suggestive of clinical depression (Yesavage, et al., 1983). The Neuropsychiatric 
Inventory (NPI) is a caregiver rated measure of 12 behavioral and psychological symptoms. The 
score rages from 0-144, with higher scores indicating more severe behavioral symptoms and 
agitation (Cummings, et al., 1994). Simple pain scales are commonly utilized by nurses and 
patients in nursing home settings, and a single number from 1-10, (with 10 signifying the 
greatest pain), is used as an index to monitor pain management. The Numeric Rating Scale 
(NRS) is a reliable and valid pain intensity scale when used for older adults (Herr, & Garand, 
2001). 
There are clear similarities between the behaviors and body language of agitation and 
physical pain. Scales for detecting and measuring pain in patients with severe dementia cannot 
easily distinguish between physical and emotional pain (Treloar, et al., 2010). Therefore, 
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considering individualized pain management and addressing depression are evidence-based 
strategies for the ongoing evaluation of a patient with BPSD. 
Although antipsychotic medications are associated with an increased risk of mortality and 
morbidity, and evidence-based guidelines recommend their use only when other interventions 
have failed, antipsychotics may be justified using a palliative care model, by reducing severe 
distress in patients who are nearing the end of life (Treloar, et al., 2010). When antipsychotics 
and other psychotropic medications are used for a target symptom causing distress, they may in 
fact relieve suffering. Not all potentially inappropriate medications can be avoided, particularly 
when used as a last resort, and when the patient or the family and the clinician agree the potential 
benefit outweighs the risk (Fick & Semla, 2012).  Antipsychotic prescribing decisions should be 
based on the patient’s individual needs, with medical, functional, social considerations, and 
quality of life with prognosis (Pretorius, Gataric, Swedlund, & Miller, 2013).  
There is evidence that antipsychotics have modest efficacy, and may improve psychosis 
and aggressive behaviors with a number needed to treat (NNT) of between 5 and 11 (Banerjee, et 
al., 2009). But conversely, some international studies link psychotropic drugs to poor QoL with 
functional and cognitive decline, and a high rate of adverse effects (Kleijer, et al., 2009; Ruths, 
Straand, Nygaard, & Aarsland, 2008; Wetzels, et al., 2010). These studies collectively suggest 
that trial dose reductions and drug cessation attempts should be attempted at regular intervals. 
Some evidence suggests that behavioral focused interventions, supportive comfort 
therapies and individualized meaningful structured activities can maximize QoL, dignity and 
comfort, but these therapies need to be standardized, consistent and documented, or it appears to 
surveyors and researchers that these non-pharmacological interventions are lacking in long-term 
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care delivery systems (Kverno, et al., 2008). Interventions and goals of care that are poorly 
documented, inconsistent, or found in multiple areas of the chart can be misleading.  
Theoretical framework 
The adoption of a new Psychotropic Risk Assessment Checklist to change practice 
patterns, and influence the prescribing culture in the nursing homes, was based on Roger’s 
Diffusion of Innovations theory (Rogers, 2003). The adoption of change in practice for care of 
patients with BPSD; specifically, an increase in non-pharmacological interventions, a decrease in 
psychotropic use, and a person-centered care plan, will affect each nursing home individually. 
The diffusion of new knowledge flows through channels, over a period of time, as 
communication and dissemination between members of a healthcare system.  Innovation 
translates to change in practice patterns as ongoing sustainable improvements in care delivery, as 
per Roger’s Diffusion of Innovations theory (Rogers, 2003). Each nursing facility is a unique 
living environment, and adapts to change at a pace that evolves over time. The early adoption of 
the assessment checklist, by the director of nursing, as an individual of influence and respect, 
demonstrates quality improvement leadership as a change agent. The quality of the evidence and 
new knowledge, the perceived relevance to the practice setting and population, and feasibility are 
important factors that determine rates of adoption. For a conceptual model of the theory see 
Figure #3. 
The Diffusion of Innovations theory is based on the assumption that certain conditions 
increase or decrease the likelihood that a new concept, product or practice will be adopted by 
members of a given culture or social system. This theory predicts that media and interpersonal 
relationships provide information, and influence others opinions and judgment. Rogers defined 
four stages of innovation: invention, diffusion or communication channel through a social 
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system, time and the social system or context. As information flows through networks, the roles 
of opinion leaders determine the likelihood that the innovation will be adopted by exerting their 
influence on audience behavior.  
Rogers defined five characteristics that determine the likelihood that an innovation will 
be adopted. These characteristics also determine the rate of adoption: 
• Relative advantage 
• Compatibility 
• Complexity 
• Trialability 
• Observability to members within the social system 
Communication, or the process of diffusion, is accomplished by members of a social 
system sharing information and reaching a mutual understanding (Rogers, 2003). 
Communication channels are mass media channels or interpersonal channels, where mass media 
are more effective in creating new knowledge, but interpersonal channels are more effective in 
forming and changing attitudes toward a new idea. Rogers asserted that most individuals 
evaluate an innovation through subjective evaluation of peers and colleagues who have adopted 
an innovation rather than on scientific research or expert opinion alone.  
Time intervals in the process of diffusion, can be measured in three different ways 
(Rogers, 2003). The first is a 5-step innovation-decision process involving, 1) an individual’s 
first knowledge of an innovation, to 2) forming an attitude toward the innovation, to 3) a decision 
to adopt or reject the innovation, to 4) implementing the innovation to 5) confirming or 
evaluating the innovation. An individual seeks information at various stages in this process to 
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confirm progression through the process and increase certainty about an innovation’s perceived 
consequences.  
The second way in which time is involved in diffusion is captured by five adoption 
categories and is based on a standard deviation-curve where very few innovators adopt the 
innovation in the beginning (2.5%), early adoptors arrive (13.5%) a short time later, followed by 
the early majority (34%), the late majority (34%), and finally the laggards who represent (16%) 
of the adoptors. Rates of adoption are influenced by the five perceived characteristics of an 
innovation previously mentioned. 
The third way in which time is involved in the rate of adoption or the relative speed with 
which an innovation is adopted by members of a social system. 
The social system represents the fourth main element in the diffusion of innovation, and 
Rogers defined it as a set of interrelated units that are engaged in joint problem solving to 
accomplish a common goal. The units of a social system may be individuals, informal groups, 
organizations or subsystems. A change agent is an individual who attempts to influence other 
members innovation-decisions in a direction that is perceived as beneficial to the organization.  
An important concept in understanding the nature of the diffusion process is the critical 
mass. Critical mass occurs at the point at which enough individuals have adopted the innovation 
so that the innovation’s further rate of adoption becomes self-sustaining. Strategies to reach 
critical mass should be targeted to the early adoptors, (13.5%) in the social system. These early 
adoptors are often influential opinion-leaders, and serve as role models for many other members 
in the organization.  
Rogers describes innovators, the first 2.5% of individuals in a system to adopt an 
innovation as unique, because they understand and apply complex technical knowledge to solve 
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problems in new ways. The innovator must be able to cope with uncertainty about an innovation 
at the time of adoption. The innovator is usually not limited by financial resources, but may 
weigh heavily against unprofitable projects. The innovator plays an important role in the 
diffusion process by launching the innovation and by importing the innovation into the 
organization from outside the organizational boundaries. Therefore, the innovator has a 
gatekeeping role in the flow of ideas into a social system.  
The early adoptors are the next 13.5 percent of the members of a social system to adopt 
an innovation. They are described as opinion leaders and speed the diffusion process. The early 
adoptors are generally respected by their peers and know that to continue to earn the respect of 
colleagues, they must make judicious innovation-decisions. The early adoptors serve to decrease 
uncertainty about an innovation by adopting it, and then sharing their perceived benefit to peers 
by interpersonal connections. 
The next group of individuals to adopt an innovation in a social system, are known as the 
early majority (34%). The early majority group adopts innovations just before the average 
member of a social system. They interact frequently with their peers, but rarely have positions of 
opinion leadership. They represent an important adoptor category because they provide 
interconnectedness in the social system’s network of members. 
The late majority is the next 34 percent of individuals in a social system to adopt an 
innovation. This adoptor category, adopts new ideas just after the average member of a social 
system, and they are likely to be influenced by increasing peer pressure. They may be skeptical 
and cautious before they motivated to make a change. The late majority group is characterized by 
having relatively scarce resources, which means they need confidence and low risk to adopt new 
ideas. 
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Rogers classified the last group of individuals to adopt an innovation as the laggards, or 
16 percent of the members of a social system. Many laggards are relatively isolated in the social 
network and their usual point of reference rests on process and patterns of the past. They may 
resist innovation and similar to the late majority, are resource limited, and may fear failure. 
Methods 
Ethical issues 
APNs and other clinicians have important professional and ethical obligations to older 
adults, with advanced dementia and behavioral disturbances. Especially challenging is the 
medical management with psychotropic medications in the setting of long-term care. Knowledge 
of the dementia disease trajectory may inform treatment decisions with a goal for palliative care 
and symptom reduction to relieve suffering and improve QoL. The ethical virtues of 
nonmaleficence (do no harm), beneficence (do good), autonomy (respect for individual rights), 
and advocacy (speaking for the interests of those who cannot speak) are based in our 
professional code of ethics, and are relevant for vulnerable populations. APNs can rely on our 
professional organization, the American Nurse’s Association’s Code of Ethics for Nurses with 
Interpretative Statements for a position statement on end of life care: 
Nursing care is directed toward meeting the comprehensive needs of patients and their   
families across the continuum of care. This is particularly vital in the care of patients and 
their families at the end of life to prevent and relieve the cascade of symptoms and 
suffering that are commonly associated with dying. (ANA, 2001, p.12) 
In an effort to provide more optimal dementia care, the tool provides a checklist to critically 
appraise the benefits and risks of psychotropic medications, and to establish the goals of care, 
including QoL measures, with shared decision-making, for person-centered care. With the 
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knowledge that nursing homes are living-environments for residents who live there, long-term 
care providers should preserve and promote QoL, as important as other health outcomes (Kane, 
et al., 2003).  
Setting 
The Psychotropic Risk Assessment Checklist was implemented in four separate skilled 
nursing facilities (SNF) over a period of eight weeks, to document the medical management for a 
total of 17 long-stay residents with BPSD. The SNFs were local to the community of Napa, 
California, and ranged in size from 50 beds to 190 beds. Two of the SNFs were contracted with 
Kaiser Permanente (KP) for skilled care. As a KP employed nurse practitioner, my caseload 
included skilled care residents in addition to a total of 92 long-stay residents, among the four 
facilities. Each facility had individual interdisciplinary teams (IDT) and leadership philosophies, 
with individual rates of adoption of new knowledge, and willingness to change. The directors of 
nursing were enthusiastic about implementing the Psychotropic Risk Assessment Checklist, and 
became the facility champion for implementation. They perceived the new checklist as quality 
improvement for a process of care delivery that was poorly documented, and located in many 
sections of the chart. The checklist is simple but comprehensive, streamlined, and inexpensive to 
implement. The checklist seemed a good fit with individual organizational missions and IOM 
philosophies; to deliver safe, efficient, equitable, timely, high-quality, person-centered care.  
Planning the intervention 
 Discussions with the administrators and directors of nursing at the individual SNFs, 
regarding their concerns with the general lack of documentation in the medical records with the 
medical management of residents with BPSD, revealed their readiness to participate in a revised 
process of care. Potential penalties related to non-compliance with regulations on inappropriate 
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psychotropic use, was an additional concern. The checklist was simple, concise but 
comprehensive, and was feasible for implementation in their organizations. It included a list of 
the resident’s medical condition and staging of dementia, target symptoms, individualized non-
pharmacological interventions employed, a complete list of psychotropic medications prescribed 
with their indications, psychotropic risk review, QoL indicators, and engaged families or patient 
proxies for shared decision-making. Additional value from the checklist comes from the 
integration of palliative care with dementia care, addressing the goals of care, with a focus on the 
resident’s experience. Engaging the IDT and psychotropic review committee at each facility, 
strengthens the care delivery process through collaboration. The checklist could be accessed and 
updated by clinicians and other IDT members, and utilized as a quarterly update and review of 
the medical management for residents with BPSD and psychotropic risk reduction. Decisions to 
attempt psychotropic dose reductions or discontinuations would be carefully evaluated and 
documented on the checklist. Engagement of the family or the patient’s proxy would be 
documented as an important part of the process. An electronic version of the checklist, by 
utilizing informatics to access psychotropic risk assessment information along the continuum, 
would meet expectations of busy primary health care physicians as high end-users. As the 
checklist evolves as a simple, concise documentation aid, with a point and click format, it may 
simplify the process of critical thinking and risk analysis in the medical management of BPSD. 
Sharing an electronic version of the checklist with colleagues and eventual spread to other Kaiser 
Permanente service areas can be accomplished by introducing the checklist at medical 
conferences and the annual long-term care summit. Dissemination of the checklist can spread 
rapidly by submitting for publication to geriatric medical and nursing journals. A complete 
project implementation Gantt Chart is included as an appendix. 
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Implementation of the project 
 Project education and implementation began in January 2013. An educational update on 
best practice guidelines on the medical management of patients with BPSD with evidence-based 
risk and safety concerns, was delivered to Kaiser Permanente nurse practitioners in the San 
Francisco bay area who worked in long-term care facilities, in February 2013. Later, in 
September, a similar educational update was delivered to KP primary care physicians in the 
Napa Medical Offices. In October 2013, an educational update was presented to interdisciplinary 
health professionals at a KP SNF Summit. A checklist concept evolved as a method to aid 
documentation and address critical thinking toward psychotropic use for residents with BPSD. 
The evolution of an electronic version of the checklist, came from discussions with primary care 
physician colleagues who were end-users and familiar with the KP Healthconnect electronic 
health record.  
How the checklist works 
The checklist is a 2-page, front and back paper form, with multiple components 
including; disease severity and prognosis, target symptoms, individualized non-pharmacological 
interventions, psychotropic drugs prescribed with indications, risk analysis, QoL indicators, and 
shared decision-making with proxy or family discussions including trial dose reductions based 
on perceived benefit and risk, and goals of care. The dementia disease trajectory, although not 
included in the checklist, helps the clinician to define dementia as a progressive and terminal 
disease. This knowledge of the temporal pattern of the disease process leading to a person’s 
death, suggests when to commence palliative care or hospice.       
The Psychotropic Risk Assessment Checklist involves the evidence-based FAST 
(Functional Assessment Staging Test) a scale that helps to predict end of life parameters for 
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dementia disease, where a score above 7 correlates with advanced disease (Reisberg, 1988). 
Stage 7c of the FAST scale has been suggested by the National Hospice Organization as an 
appropriate point to enroll patients with a primary diagnosis of dementia into hospice (National 
Hospice Organization, 1996). At stage 7c or greater, more than two-thirds of persons with 
dementia will die within 6 months (Hanrahan, Raymond, McGowen, & Luchins, 1999). Patients 
cannot be staged using the FAST criteria unless their disease progresses in the ordinal sequence 
of the scale (Luchins, Hanrahan, & Murphy, 1997). It is important to note that not all patients 
with dementia follow the progression of disease designated by the FAST. The Psychotropic Risk 
Assessment Checklist prompts the clinician to identify the type, severity or stage of dementia, 
and considers other co-morbid conditions that may affect the clinical course and treatment 
choices.  
The target symptoms of most concern, or distress to the patient, are identified and 
defined.  Expert consensus calls for non-pharmacological strategies to be first line treatment, and 
should be designed for each individual patient according to patient preference, or what is 
beneficial to ameliorate the target symptoms. Feasible and effective non-pharmacological 
interventions may include (e.g. time outside, exercise or movement, music or sing-a-longs, 
animal assisted therapy, or scheduled family visits). Many patients with mild to moderate BPSD 
will not need pharmacological treatments if non-pharmacological interventions are effective, and 
utilized consistently. However, some patients with advanced disease and severe symptoms may 
inevitably need psychotropic treatments, and the checklist matches the prescribed medication 
with a specific target symptom of concern. 
The checklist provides a condensed synopsis of evidence-based psychotropic risk 
concerns, such as fall risk, extrapyramidal side effects, or the cumulative effect of anticholinergic 
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burden, as well as QT interval prolongation. New evidence from Rossom, et al., (2010), suggests 
lower doses of antipsychotic medications are associated with lower risk for mortality and 
morbidity, and may guide treatment decisions for trial dose reductions.  Using the lowest 
possible dose to achieve efficacy is an important clinical tip for prescribing for older adults.  
Evidence of QoL measures for dementia patients at the end of life, suggest strong 
correlatations with decreased pain, depression and agitation. The Psychotropic Risk Assessment 
Checklist prompts clinicians to address pain management, symptom reduction, depression 
management, and sleep quality with interventions to improve QoL. The qualitative value of the 
checklist lies in the integration of palliative medicine with dementia care, with comfort-focused 
strategies to relieve suffering of those who are near the end of life. The checklist acts as a guide 
to inform discussions with patient’s family or proxy regarding prognosis and goals of care. When 
optimizing the care of persons with dementia, and addressing the goals of comfort and shared 
decision-making, the use of psychotropic medications may be justified in the management of 
debilitating symptoms (AGS, 2012). In this framework of therapeutic analysis, the perceived 
benefits of psychotropic treatments may exceed the risks, in certain individuals who are near the 
end of life. In cases with extended psychotropic therapy, the decision to mainstay or decrease the 
psychotropic burden, is based on the patient’s QoL benefit, or preference for risk reduction by 
trial dose reduction. Clear documentation of a benefit/risk statement regarding a patient’s 
psychotropic use, is a key value of the Psychotropic Risk Assessment Checklist. 
The checklist may become more widely utilized in long term care settings to provide 
clinicians and IDT members with an evidence-based method for risk appraisal, to inform the 
selection of appropriate non-pharmacological approaches, and lowest risk options for 
psychotropic therapy, if necessary. Researchers may find the checklist beneficial in designating 
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performance measures and outcome statistics, risk management and QoL indicators for those 
with BPSD in diverse settings. This checklist is not a scale, and does not stratify risk or predict 
outcome measures for mortality or morbidity indices, for example. Nor has the checklist been 
endorsed as policy or best practice by Kaiser Permanente. 
Planning the study of the intervention 
 The checklist represents a process improvement with a focus on person-centeredness, 
engaging the IDT, utilizing an evidence-based process of critical thinking and analysis, and 
informatics. Retrospective chart review was planned to capture measures of increased utilization 
and documentation of non-pharmacological interventions and shared decision-making with 
residents and their families or proxy. By the essence of using the checklist, where a chaotic 
process existed before, it was assumed that utilization and documentation of these measures 
would improve. There were no actual baseline measures to compare, and it was assumed that if 
non-pharmacological interventions were undocumented, that they were not done, or done 
inconsistently.  
 A gap analysis can be viewed as an appendix. 
Methods of evaluation 
 A full SWOT assessment with known internal and external forces can be viewed 
as an appendix. The Psychotropic Risk Assessment Checklist supports the Kaiser Permanente 
(KP) culture of knowledge sharing and evidence-based practice, and is congruent with the KP 
mission to provide high-quality and cost effective care to the members and communities it 
serves. The checklist also supports the individual nursing home missions, and was perceived as 
an innovation that adds value to their current care delivery system. The checklist is easily 
accessed by the IDT members, and enhances collaboration and expertise of other health 
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disciplines. Each individual nursing home has unique leadership styles and resource constraints 
and therefore, different rates of adoption to change. The checklist satisfies CMS and national 
initiatives to improve care for patients with BPSD and reduce psychotropic use. The checklist 
may reduce potential external pressures posed by regulatory agencies and penalties with 
inappropriate psychotropic use, and improve compliance with laws and regulations concerned 
with prescribing practices. 
 Retrospective chart review was conducted to collect data for increased documentation of 
multiple components of BPSD management. The utilization of the Psychotropic Risk 
Assessment Checklist facilitated concise documentation on the type and severity of dementia, the 
disease staging (to integrate palliative medicine into the goals of care), the target symptoms 
causing distress, the effective non-pharmacological interventions, the psychotropic drug 
prescribed, the dose and indication, adverse effect monitoring, and QoL indicators. The decision 
to implement a trial dose reduction of psychotropic medications was a collaborative decision 
with the patient, family, or members of the IDT and documented on the checklist. Finally, the 
checklist documents and acknowledges discussions with family or proxies on shared decision-
making and goals of care (e.g. palliative, comfort, hospice). The checklist will be utilized as a 
quarterly clinical assessment for all patients with BPSD who use psychotropic medications. By 
the very essence of using the checklist as a new process, there will be enhanced documentation 
of the various components in the management of BPSD, that were previously undocumented, 
and measured as a process improvement.  
 The qualitative impact results were captured by a phone survey conducted to elicit feed 
back from the directors of nursing who were the Quality Improvement Coordinators and lead the 
psychotropic review process at each nursing facility. An informal phone survey was also 
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conducted to patient’s family or proxy, to capture evaluative remarks about the provision of care 
for patients with BPSD, and satisfaction. 
Analysis 
The methods used to capture data included both quantitative and qualitative strategies and 
are still emerging. Quantitative and qualitative metrics include, 1) increased utilization and 
documentation of non-pharmacological interventions, 2) improved satisfaction with care, and 
shared decision-making, 3) improved QoL measures, and 4) qualitative impact results from the 
IDT. Additional future outcomes include reduced psychotropic use with cost savings, improved 
public benchmarking, and improved survey results from oversight and regulatory organizations. 
Developing a formal quarterly patient/family or proxy survey will measure perceptions with care 
delivery. This kind of data provides rich content for evaluating the project impact. Clinician 
satisfaction with the Psychotropic Risk Assessment Checklist comes from comprehensive but 
concise documentation of BPSD management. The checklist simplifies the complex task of 
weighing benefits and risks of psychotropic use, and risk reduction. Patients and families who 
are satisfied with their care, is an additional value. An electronic version of the checklist will 
improve clinician access and end-user efficiency. 
The project implementation is primarily nonlinear, with a less defined structure. There 
are anticipated outcomes that influence care management, with improved documentation of a 
care delivery process that was previously fragmented and disorganized. Other important 
anticipated outcomes extend to influence culture change with psychotropic prescribing, and 
increased emphasis on non-pharmacological interventions. Metrics collected are both simple, as 
with retrospective chart review, and other complex metrics emerge from organizational impact 
and culture change, as outcomes with care for patients with BPSD. 
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Results 
Program evaluation 
 The checklist was implemented with 17 long-stay residents with BPSD on psychotropic 
medicines, with a mean age = 86.7 years (range = 65-97 years). There were 16 females (94%), 
and 1 male (6%). From a total of 92 long-stay residents on my case-load, there were 17 residents 
on psychotropic medications for BPSD management which represented 18.4% residents on 
psychotropic medicines. The Mean FAST score for dementia severity was (6.71); a score over 7 
represents severe dementia. 
The checklist improved documentation of non-pharmacological interventions, for the 
management of BPSD, on all 17 residents. Psychotropic dose reductions were documented on a 
total of 7 residents, which represented a 41% reduction in psychotropic medication use during 
the eight week project, conducted January 1, 2014 through February 28, 2014. One resident 
experienced a relapse of severe symptoms after dose reduction, and after a gero-psych 
evaluation, had a subsequent increase in psychotropic medications. All four of the directors of 
nurses reported, the checklist represented quality improvement by increased documentation of 
the non-pharmacological interventions employed for each resident, the target symptoms of 
distress, the dementia disease severity, the psychotropic medications prescribed and indication, 
adverse effect monitoring, quality of life indicators, and goals of care. Each of the directors of 
nursing, or facility champion, readily adopted the checklist into process improvement, because it 
was concise, streamlined, comprehensive, and had a good feasibility fit for their residents and 
facility. There was no cost associated with the tool implementation to the facilities, and three of 
the four directors of nursing believed there may be significant cost saving with decreased 
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psychotropic medication use, and a potential decrease in penalties associated with inappropriate 
medication use.  
 Additional qualitative impact measures were elicited from a phone survey conducted with 
patient’s family or proxies. Most, (72%) expressed appreciation and increased satisfaction by 
being informed, and included in the process of developing realistic goals of care, in the context 
of end stage dementia disease, with perceived QoL, and shared decision-making. Some families 
or proxies commented that these discussions helped them feel significantly better about the care 
provision, and decreased their worries and perceived burden of care. 
Discussion 
Summary 
 We know the treatment for late life BPSD is particularly challenging because of debility 
and frailty of older adults, existing comorbidities, and polypharmacy contributing to risk of 
adverse drug events. Still, clinicians have been in a quandary lacking clear guidelines and tools 
for clinical decision-making and few options for effective treatments for those who suffer with 
the debilitating symptoms of BPSD. Nursing home clinicians who consider treatment options for 
late life BPSD strive to ease the burden of suffering and the disease, and influence quality 
outcomes for end of life care. A person-centered palliative care approach offers a clinical 
pathway that is compatible with the dementia disease trajectory, and should be introduced as 
patients and families or proxies consider treatment choices and advanced directives.  
This quality improvement project provided a novel approach to the management of long-
term residents with BPSD. The checklist was rapidly adopted by each long-term care facility as 
an innovation because it supported the over-all mission of each individual organization. Early 
integration of palliative medicine with dementia care, promoted enhanced identification of 
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realistic goals of care, with person-centered outcomes, and improved patient and care giving 
experience.  
The organizational leadership team and stakeholders (Administrator, Director of Nursing, 
and Medical Director) at each individual implementation site played an essential role in system 
integration and sustainability of a new care process (Kolanowski & Van Haitsma, 2013). More 
in-depth strategic planning up front should have included meetings and partnership with these 
key stakeholders. Planning meetings with each individual director of nursing was critical, but 
including the other members of the leadership team would have further boosted our efforts. 
Another important lesson learned, is articulating the vision of person-centered care early into 
project planning. When the vision is clearly shared, the quality improvement project is sure to 
spread and succeed, and increases the likelihood of being sustained.  
This quality improvement project has important implications for Advanced Nursing 
Practice. Developing, testing, and implementing new nursing care models for treating persons 
with BPSD and vulnerable populations has been identified as a major emphasis for 
gerontological nursing (Kolanowski & Priven, 2006). As new evidence and guidelines emerge in 
the care of the geriatric patient with BPSD, new knowledge will need continual translation to 
practice, using the strength and diversity of the interdisciplinary team.  
Educational programs to update and inform clinicians and IDT members on best practice 
recommendations for non-pharmacological and pharmacological interventions will improve 
clinical competencies in the management of BPSD and support sustainability in practice changes 
over time.   
The Psychotropic Risk Assessment Checklist changes the paradigm of care delivery, 
recalibrating the goals of care for comfort, instead of health maintenance, and permits less 
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restrictive treatment modalities. The checklist provides a method to restructure care services that 
incorporate the entire IDT to work collaboratively to meet the needs of the patient. Utilizing the 
expertise of pharmacists, dieticians, gero-psych practitioners, therapists, and nurses strengthens 
the care delivery system. More planning is needed to develop a quality team to include 
pharmacist participation. Their expertise and involvement in the medical management of 
psychotropic medications cannot be underestimated. As clinical pharmacists complete their 
routine chart review, their input into the checklist and plan of care, with recommendations and 
modifications is highly valued.  
  The checklist was feasible, and streamlined as a quality improvement strategy for 
clinicians to critically appraise the medical management of all patients with BPSD, for risk 
reduction and symptom amelioration.  
The dissemination plan for the Psychotropic Risk Assessment Checklist will proceed 
towards submission for publication and regional presentations to share with other KP service 
areas. Additionally, moving from a paper form to an electronic version of the checklist will 
enhance documentation and user accessibility. As each long-term care facility uploads the 
checklist to their own electronic health record systems, there will be further spread and increased 
generalizability. 
  
Relation to other evidence 
The current emphasis on first line approach with non-pharmacological interventions for 
BPSD represents an evolving culture change at each individual facility. Regardless of the current 
evidence base, patient and family preferences should guide clinical decision-making. Clearly, 
caregivers and family members are eager to discuss what interventions have helped and which 
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ones have not helped, and the Psychotropic Risk Assessment Checklist provides a unique and 
concise format to incorporate these behavioral interventions into the care plan.  
Other long-term care facilities will be looking for ways to increase utilization and 
documentation of non-pharmacological interventions and decrease inappropriate use of 
antipsychotic medications. So far, an emphasis on education and training for clinicians, direct 
care staff, and caregivers has the best efficacy and long effect. National benchmarking and public 
reporting of antipsychotic utilization rates on the CMS website, Nursing Home Compare is still 
new and data is emerging.  
Qualitative feedback responses from the directors of nursing indicate, they value the 
opportunity to improve documentation of non-pharmacological interventions, because the lack of 
documentation may lead to misguided evaluations from oversight organizations. Partnership with 
individual nursing home stakeholders to adopt a variety of non-pharmacological strategies with 
sufficient allocation of resources for staff training and support is needed. 
Kolanowski’s Toolkit for Promoting Positive Behavioral Health: A Non-pharmacological 
Toolkit for Senior Living Communities gives comprehensive and practical guidance to assist 
long-term care facilities to identify the most optimal and feasible approaches that match their 
residents and individual capabilities. The challenges they face as resource-limited organizations 
are formidable, although low-cost and efficacious approaches are good solutions for the complex 
problems in the management of BPSD.  
Long-term care facilities are living-environments, unlike hospitals, and need to promote 
comfortable environments for senior living. Many basic needs are met in long-term care 
facilities, because they are therapeutic living environments, where caregivers are trained to 
provide adequate food, clothing, hygiene, safety, and rest. However, other more complex needs 
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may require additional services structured for behavioral and psychological problems, 
meaningful social activities, cultural or spiritual needs that affect QoL (Kolanowski, & Van 
Haitsma, 2013). The allocation of resources from basic levels of care toward more complex 
potentially unmet needs may have a positive impact on health-related QoL for residents with 
advanced dementia (Scholzel-Dorenbos, Meeuwsen, Olde Rikkert, 2009), and this has important 
implications for clinical practice and for health policy and planning. Ongoing evaluation and 
management of pain, depression, and behavioral disturbances are evidence-based approaches to 
improve QoL for individuals with advanced dementia, and should be emphasized. 
Attention to quality of life for residents in nursing homes is still emerging but for 
residents with advanced dementia and BPSD, clearly an emphasis on pain, depression, and the 
target symptoms of BPSD has the greatest potential to make the most difference for those 
persons. 
Please see attached synthesis of evidence of literature review as an attachment, for QoL 
for persons with advanced dementia in long term care settings. 
Barriers to implementation/Limitations 
Efforts should be made to design and implement improved informed consent processes 
with shared decision-making with psychotropic use. A discussion with disclosure of potential 
benefits and risks of psychotropic medications with thorough documentation is required in long-
term care. APNs are capable of facilitating these processes, and are largely responsibile for the 
clinical over-sight of psychotropic medications in long-term care settings. Legislative action to 
remove scope of practice barriers should be examined, since California law under the Health and 
Safety Code prohibits APNs from obtaining informed consent or prescribing antipsychotic 
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medications in these settings. Off-label prescribing of psychotropic medicines for BPSD is an 
additional concern for all clinicians and healthcare professionals.   
Clearly articulating a vision for person-centered care and incorporating that vision into 
strategic planning (Kolanowski & Van Haitsma, 2013) is critical for the culture change 
movement. Moving away from the medical model of care, towards a person-centered 
philosophy, involves every member of the IDT, administrative and stakeholders alike. This 
vision should be foundational to any quality improvement project. 
Identifying a champion at each facility, who is an expert on the Psychotropic Risk 
Assessment Checklist is essential to facilitate the ongoing implementation and sustaining the 
quality improvement effort. The director of nursing at each facility worked well in this 
leadership role, to advance the culture change and project implementation, however other 
disciplines will provide additional expertise.   
Time limitations created a barrier to further develop a formal quarterly patient/family 
satisfaction survey. A survey to include medical management with antipsychotics and other 
psychotropic medications will be an effective strategy for a continuous quality improvement 
process, to measure ongoing quality outcomes and guide clinical decision-making. Other 
outcome measures of perceived management of pain, depression, and BPSD symptoms should be 
included in the survey as components of patient/family satisfaction with care. Conducting 
patient/family satisfaction surveys will provide important information about what patient needs 
may be still unmet, and provides an opportunity for patients or families, and caregivers to reflect 
on whether an intervention has made a meaningful difference in their life. Information from 
surveys can be an important link between the patient and family needs and health care services 
provided.  
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Interpretation 
Continued efforts to improve care for older adults with BPSD by utilizing the 
Psychotropic Risk Assessment Checklist will require a longer period of time to verify and 
evaluate practice improvements, by measuring continuous quality outcomes and sustained 
change. Outcomes such as improved staff satisfaction, improved state surveillance, continued 
accreditation, and averting potential penalties with psychotropic use, were not yet realized. 
Nursing homes may capture improved antipsychotic utilization rates with national benchmarking 
status as they proceed with trial dose reductions and stop medications that are not needed.  
The degree of agreement regarding the desirability of, or the need for change was 
enthusiastic among the four directors of nurses. One director of nurses has since retired, and so 
new relationships will evolve over time as an ongoing process of sustainability in practice 
improvement. The director of nurses at each facility was the key change agent, and was the 
leader of the IDT psychotropic review process. There are important implications for future 
professional and staff development by allocating resources for education, and for direct care staff 
and caregiver support. Care of older adults with BPSD will require new skills and competencies 
as knowledge of best practices emerge. 
A new checklist must be quick, easy, and accessible for busy clinicians to use. Time 
constraints are a constant reality for clinicians who strive to deliver person-centered, 
comprehensive, safe, timely and equitable care. As the checklist evolves as an electronic version 
on the EHR, and disseminates to diverse settings along the continuum of care, it becomes easily 
accessible to clinicians, nurses, pharmacists, and others on the IDT. Then, it will impact care for 
patients with BPSD, and facilitate responsible risk management for psychotropic use. It is 
essential that APNs take a leadership role in the development and implementation of guidelines 
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for improved medication management among older adults. Nurses must stay engaged in the 
critical appraisal of psychotropic medication use and lead the culture change in improved 
implementation of non-pharmacological alternatives. 
Conclusion 
 The Psychotropic Risk Assessment Checklist is innovative, modern, evidence-based, and 
congruent with the CMS national initiatives to reduce unnecessary and inappropriate 
psychotropic and antipsychotic use. However, the checklist provides a pathway for clinicians to 
justify these medications for some individuals with advance dementia who may be near the end 
of life, where symptom reduction achieved by a combination of non-pharmacological and 
pharmacological treatments, may improve their QoL. As clinicians interweave palliative 
medicine with dementia care, the Psychotropic Risk Assessment Checklist informs decision-
making, leads to improved documentation, and engages the IDT in the provision of person-
centered care. Improved outcomes and QoL for older adults with advanced dementia and BPSD 
is a prominent concern for all long-term health professionals. 
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Picture 1 
 
Dementia Disease Trajectory retrieved from online/data_dx/reg/1020/img/1020-4-
iline.gif 
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Name:_Mr O___________________________________MR#_________________Date_____________ 
 
Psychotropic Risk Assessment Checklist for Patients with BPSD 
 
Type and Severity of Dementia: (check which applies) 
_X_ Alzheimer’s  __ Vascular __ Lewy Body Dementia  _X_ Other ______________________ 
Other Co-morbidities: __diabetes __CHF_X_ CVA__Other_CAD, Anemia w/o further w/u________ 
_X__advanced age: 88 y/o 
 
Staging with (FAST) Functional Assessment Staging Test:  
Stage Stage Name Characteristic MMSE score 
1 Normal Aging No deficits 29-30 
2 Poss Mild Cog Impairment Subjective functional deficit 28-29 
3 Mild Cognitive Impairment Objective functional deficit 
interferes w complex tasks 
24-28 
4 Mild Dementia ADLs become affected 19-20 
5 Moderate Dementia Needs help selecting proper 
attire 
15 
6a Moderately Severe Dementia Needs help putting on clothes 9 
6b Moderately Severe Dementia Needs help bathing 8 
6c Moderately Severe Dementia Needs help toileting 5 
6d Moderately Severe Dementia Urinary incontinence 3 
6e Moderately Severe Dementia Fecal incontinence 1 
7a X Severe Dementia Speaks 5-6 words during day 0 
7b Severe Dementia Speaks only 1 word clearly 0 
7c Severe Dementia Can no longer walk 0 
7d Severe Dementia Can no longer sit up 0 
7e Severe Dementia Can no longer smile 0 
7f Severe Dementia Can no longer hold up head 0 
 
Target Symptom causing distress or danger to the patient: __ hallucinations _X_delusions  __ severe 
anxiety_X_combativeness _X_persistent yelling _X other _Insomnia/Sleep Disorder_ 
 
Non-pharmacological Interventions: _X_time outside _X_ exercise or movement_W/C rides_healthy- snacks __ 
puzzles or activities __ family photo album __ pet or stuffed animal 
_X_ scheduled family visits __ purse or wallet to hold __ hair brushing  __ music__other___ 
 
List Psychotropic Drugs: dose and frequency and target sx 
1. _Sertraline 100mg q day for agitated depression/grieving_______________________ 
2. _Quetiapine 100mg q HS for delusional disorder_-DC’d________________________ 
3. _Donepezil 10mg q morning_for dementia_with behavioral disturbance____________ 
4. _Lorazepam 0.5m_twice daily as needed for agitaton -DC’d_____________________ 
5._Olanzapine 5mg q HS x 5 days, then 10mg, then 15mg q HS delusional disorder w distress 
6._Depakote Sprinkles 250mg q AM_x 5 days then twice daily for mood stabilizer, agression 
Pain Management: 
1.______________________________________________________________________ 
2.______________________________________________________________________ 
3.______________________________________________________________________ 
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Evidence suggests lower dose poses lower risk:    (Rossom et al., 2010). 
Olanzapine < 2.5 mg /day; Quetiapine < 50 mg/day; Risperdone < 1 mg /day.  
   
QT interval Risk:   last QTc__420_____________date ____________ 
 
Fall Risk: ___ Patient ambulates __ unsteady gait _X_Patient nonambulatory 
 
       Adverse effects or anticholinergic burden: __dysphagia __EPSE__hypotension _X_sedation 
 
QoL :  _X_ target symptom reduction  __ pain managed _X_ depression managed_X_sleep quality 
 
Discussion with DPOA and family: date __done_______________ Outcome: palliative care/comfort care/ 
hospice: Comfort care is priority, family wants to avoid hospitalizations, Hospice care when indicated 
 
_X_consider dose reduction _in 4 week intervals______________________________________   
___dose reduction not recommended because of QoL benefit 
___dose reduction may put patient at risk of symptom relapse or emotional instability 
_X patient has a good response to current regimen without adverse reaction and benefit exceeds risk. 
 
Reference: 
Freeman, C., Joska, J. (2012). Management of behavioral and psychological symptoms of dementia. Continuing 
Medical Education, 30(4). 
Reisberg, B. (1988). Functional assessment staging (FAST). Psychopharmaco/Bullitin, 24, 653-569. 
Rossom, R., et al. (2010). Are all commonly prescribed antipsychotics associated with greater mortality in elderly 
male veterans with dementia? J AGS, 58,1027-34. 
RECOMMENDED DOSES IN ELDERLY PATIENTS 
Medication Additional Notes 
Antidepressants 
     SSRI  
     
 SARI (serotonin 2 antagonist/
reuptake inhibitor) 
Citalopram 20 mg/day: 
initiate at 10 mg 
Sertraline 50-100 mg 
Trazodone 25 mg at HS 
Few CYP450 interactions 
Cholinesterase inhibitors Donepezil 5-10 mg during 
the day 
GI side-effects are 
common 
NMDA receptor antagonist Memantine 10 mg twice 
daily 
Dizziness and headache 
may occur 
Anticonvulsants Sodium valproate 10-15 
mg/kg in divided doses 
Start with smaller dose 
and titrate up 
Antipsychotics 
     Typical 
     Atypical 
 
Haloperidol 0.5 -1 mg/day 
Risperidone 0.5 mg twice 
daily: may initiate at 0.25 mg 
twice daily 
Quetiapine 25-50 mg at HS 
Olanzapine 2.5 – 10 mg / day 
Watch for EPSE, may 
increase prolactin, 
hypotension, sedation 
 
Anitcholinergic effect 
mild-mod 
 
Freeman & Joska, 2012 
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SWOT Analysis 
A Psychotropic Risk Assessment Checklist for Clinicians and IDT 
 
 
 
 
 
INTERNAL to the 
Organization 
 
STRENGTHS: 
 
• KP culture approves 
knowledge sharing & EBP 
• Supports KP mission and 
individual SNFs 
• Provides guide for licensed 
healthcare workers 
• Involves SNF IDT regionally 
• Checklist promotes 
collaboration with 
pharmacists, nurses, and 
clinicians 
• Good feasibility for SNFs 
• Improved documentation 
for person-centered care 
and QoL indicators 
• Patient/family satisfaction 
 
 
WEAKNESSES: 
 
• Practice change 
resistance 
• Clinicians preconceived 
ideas about best 
practice standards 
• Each SNF has individual 
culture & demands on 
resources 
• Time constraints for 
busy clinicians 
 
 
 
Found in EXTERNAL 
Environment 
 
OPPORTUNITIES: 
 
• Satisfies CMS initiative to 
increase awareness of AP 
utilization  
• Supports community 
nursing homes 
• Improves transparency 
ratings for nursing homes & 
quality measures re: AP use 
• Lower costs of SNF care by 
decreased AP utilization 
• Meets criteria for 
certification surveys 
 
THREATS: 
 
• Potential regulatory 
agency penalties for AP 
use 
• Potential litigation 
threats for 
noncompliance with 
laws and regulations 
• AP use benchmarked on 
public websites as 
quality indicator 
• Drug costs are rising 
• Liability risk with off-
label prescribing 
Figure 2 
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Table 1. Review of Non-pharmacologic Approaches for Treating Behavioral and Psychological
Symptoms of Dementia 
Type of Non-
Pharmacologic
Approach
Description/ Specific Approaches
Efficacy for Reducing Behavioral and Psychological
Symptoms of Dementia
Sensory
Stimulation
Approaches
Sensory stimulation approaches focus on stimulating the senses
of the person with dementia. The aim of these approaches is to
respond to the unmet needs for stimulation, to enhance the
senses and to achieve therapeutic effects such as pain control,
relaxation and reduction of anxiety. Some sensory stimulation
approaches are informed by physiological models regarding the
calming influence of sensory touch or proximity associated with
some techniques such as massage. Examples include:
Aromatherapy
Light therapy
Massage and touch therapy
Music therapy
Snoezelen Multisensory Stimulation Therapy (MSS)
Transcutaneous Electrical Nerve Stimulation (TENs)
White Noise
Music therapy has demonstrated efficacy in reducing agitation
(albeit for short periods of time) among persons with dementia,
although overall study findings have been inconsistent. Various
types of music therapy have been rigorously tested including
gentle songs and individualized music therapy.
MSS combines light, music, tactile, and aroma therapies.
Findings regarding the effect of MSS on behavioral symptoms
are inconsistent but some preliminary randomized trials have
demonstrated improved short term BPSD outcomes when using
Snoezelen as well as other positive experiences associated with
the treatment, meriting further testing.
Several RCTs testing TENs have demonstrated no effect on
BPSD. There is no evidence to support the use of TENs to treat
behavioral symptoms.
Insufficient evidence exists to recommend the use of white
noise in treating behavioral symptoms.
Insufficient evidence exists to recommend light therapy in
reducing behavioral symptoms.
Massage and touch therapy has demonstrated a moderate
effect on BPSD, specifically agitation.
Aromatherapy has demonstrated moderate efficacy in reducing
agitation, however more rigorous research is needed.
Behavior
Management
Approaches
Behavior management approaches are intended to support
adaptive behavior of people with dementia through reinforcing
certain kinds of social behavior and reducing behavioral
symptoms through, for example, ignoring the behavior.
Examples include:
Habit training
Communication training
Cognitive-behavioral therapy
Individualized behavioral reinforcement therapies
Inconsistent study results and limited methodological rigor
provide insufficient evidence to support the use of behavioral
management techniques at this time.11,15
Cognitive/Emotion-
Oriented
Approaches
Cognitive/Emotion-Oriented Approaches focus on eliciting
positive emotional behavioral responses. Examples include:
Reminiscence therapy
Simulated Presence Therapy (SPT)
Validation Therapy
Reality Orientation
Currently, evidence does not support the use of any of these
approaches for BPSD. There is limited and inconsistent evidence
regarding the use of cognitive/emotion-oriented interventions.
Some of these interventions, such as simulated presence
therapy (SPT)) and reality orientation may actually have an
adverse effect in some persons with dementia and are not
recommended for treatment of BPSD.
Structured
Activity
Approaches
Structured activity approaches may include recreational activities
as well as certain forms of exercise on a regular basis. The goals
of structured activity approaches are often to develop and/or
stimulate the social, cognitive and physical abilities of persons
with dementia and to reduce boredom. Examples include:
Exercise
Recreation activities
There is insufficient evidence to conclude the effects of
exercise interventions or structured activities on BPSD; this is
largely due to methodological limitations of existing studies.12,16
There is also limited evidence regarding the effect of exercise
on BPSD, however, other benefits of exercise programs such as
improved sleep may merit their use depending on individual care
needs.15
Social Contact
Approaches
(with real or
simulated
stimuli)
Real or simulated social contact approaches may include face-to-
face interaction, group activities or audiotapes from family
members. Social interactions are believed to produce positive
mood/affect and to subsequently reduce BPSD17. As nursing
home residents also experience boredom and social isolation,
social interaction is believed to generally improve the well-being
of people with dementia. Examples include:
Animal-assisted therapy
One-on-one interaction
Simulated presence therapy (i.e. simulated family presence)
While Animal-Assisted Therapy (AAT) has demonstrated
preliminary positive findings, the current evidence base is very
limited and includes primarily non-randomized, very small scale
studies. Additional research is needed to understand whether
AAT effectively reduces BPSD.15
There is currently an insufficient evidence base to support the
efficacy of one-on-one interaction for reducing BPSD, however
further testing of this approach is merited because preliminary
work suggests that people with dementia benefit by being
engaged in social contact.18-2011,15
There is currently inadequate evidence to recommend the use
of simulated-presence therapy and it may have an adverse effect
in some individuals.15
Environmental
Modification
Approaches
Environmental modification approaches focus on matching the
environment to the needs of the person with dementia. This can
be done in different ways by providing conditions that help to
maintain the person's autonomy and independence, create a
home-like atmosphere and thereby reduce the level of stress.
The approaches are often designed specifically to reduce
wandering behaviors, or mood/sleep disturbances. Examples
include:
Wandering areas
Natural/enhanced environments
Reduced stimulation units.
Environmental modification interventions have not
demonstrated efficacy in reducing BPSD.>11,15
Clinically-
Oriented
Approaches
Clinically-oriented approaches are generally (but not always)
multi-faceted and aim to guide providers in relieving the
underlying unmet needs or causes contributing to BPSD. The
intended outcomes include reducing the use of psychotropic
drugs and BPSD, along with improving other health outcomes.
Examples include:
Pain management
Comprehensive assessment
Restraint removal
Decision-support approaches
Delirium recognition and management
Most of these interventions have demonstrated positive (not
necessarily significant) effects in reducing BPSD but few have
been tested in rigorous trials and as a result are not included in
many systematic reviews.
A systematic approach to pain management has been shown
to significantly reduce agitation in nursing home residents with
moderate to severe dementia.
Individualized interventions that utilize a systematic algorithm
to support clinical-decision making demonstrate strong potential
for treating and managing BPSD and unmet needs of persons
with dementia.21,22 Since these approaches are particularly
promising, more information is provided later in this document.
Staff-training
Approaches
(See also
Education and
Leadership
Development
section of
Toolkit)
Caregiver development as an approach is intended to increase
the knowledge of staff who are called upon to respond to BPSD.
The aim of this type of approach is to reduce behavioral
symptoms and the stress caregivers experience themselves.
Most staff training approaches are educational or psychosocial
and teach:
Communication skills
Person-centered bathing or towel bathing23
Minimizing care-resistant behaviors during oral hygiene24,25
Strategies for responding to needs of persons with dementia
Understanding and responding to BPSD
Generally, findings from staff-training approaches demonstrate
limited sustained improvement in BPSD and suggest that
continual training or reinforcement are needed to influence
behavior change. These studies have produced inconsistent
findings for the strategies used and are difficult to evaluate due
to methodological limitations, as such insufficient evidence exists
at this time to support the efficacy of most staff-training
approaches for reducing BPSD. Some specific approaches merit
replication in a more rigorous manner. 11,14,15
Person-
centered Care
Approaches4,8
The concept of person-centered care is to train care providers to
focus on the person during the task rather than the task itself.
This training may also emphasize abilities-focused care and
maximizing comfort An example of a person-centered care
approach to reduce agitation includes:
Person-centered bathing or towel bathing23
Use of person-centered bathing and towel bathing has
demonstrated reduced agitation and aggression during bathing
experiences.23
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Conceptual Model 
  
Diffusion of innovation model.
Source: Rogers (1995) 
 
http://www.tcw.utwente.nl/theorieenoverzicht/Theory%20clusters/Communication
%20and%20Information%20Technology/Diffusion_of_Innovations_Theory.doc/
 
 
 
Figure 3 
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Case Presentation 
  The following case presentation demonstrates how the Psychotropic Risk Assessment 
Checklist informs clinical decision-making, substantiates a clear benefit/risk analysis, and 
enhances documentation of non-pharmacological, pharmacological interventions, and QoL 
outcomes. It also illustrates the role of APNs working in collaboration with IDT members, to 
manage residents with BPSD in a long-term care setting.  
Mr. O is an 88 year-old African American retired Baptist minister with Alzheimer’s 
disease (AD) for seven years, and recently admitted to a nursing home for custodial care because 
his wife who cared for him at home has died. His medical history is remarkable for stroke, 
Coronary Artery Disease with stent placement, and a several year history of anemia with 
intermittent rectal bleeding that was not fully worked up because of his inability to tolerate the 
gastrointestinal prep for a colonoscopy. A gastrointestinal evaluation was postponed because a 
hospital-based palliative care and family conference determined Mr. O’s debility and dementia 
progression was significant and the goals of care were re-established for comfort and symptom 
management.  
Mr. O is unable to make healthcare decisions and his daughter is his DPOA. He has a 
POLST form for No CPR with Comfort Care and no artificial feeding tubes. Mr. O has 
moderately severe dementia on the Functional Assessment Staging of Alzheimer’s Disease 
(FAST stage 7) criteria. The nursing home interdisciplinary team (IDT) requested a medication 
review after Mr. O had several falls with night-time wandering and elopement attempts. Mr. O’s 
psychotropic medications included sertraline 100 mg orally daily, quetiapine 100 mg orally 
every night, donepezil 10 mg orally every night, and lorazepam 0.5 mg orally twice a day as 
needed for agitation. The staff nurses reported Mr. O has an unsteady gait, frequent delusions, 
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physical and verbal aggressive behavior, and frequent attempts to leave the building because he 
is looking for his wife or his car. These behaviors occurred mostly on the evening and night 
shifts. Mr. O enjoys brief time outside but is unable to calm down or participate in activities due 
to his short attention span and inability to focus. He wants to be pushed around in his wheelchair 
to be in constant motion, and requires 1:1 staffing, except when his family is visiting, which 
poses a significant challenge.  
The NP reviews his medical history and recent labs, completes a physical exam and 
considers possible comorbidities such as an acute illness, pain or depression with grieving the 
loss of spouse and adjustment to a new environment. The NP reviews the social history 
completed by the LSW and noted Mr. O has two grown children and nine grandchildren who 
visit daily and participate in his care. He has a chronic sleep disorder and for many years his wife 
had trouble with his nighttime wandering, irritability and restlessness. Mr. O is unaware that his 
wife has died and often calls for her and demands to see her. He is able to remember that he was 
a minister and is able to recall his children’s names. The NP finds Mr. O irritable on exam, using 
sarcastic and hostile language. She does not detect or elicit pain on palpation or movement of 
any extremity. The NP orders a UA with culture and sensitivity, discontinues the lorazepam 
because of fall risk, changes the donepezil dose to the morning for maximum efficacy for 
behavior, and calls the gero-psyche team for a referral. The NP reviews the care plan with the 
family and DPOA, and the staff nurses, answers questions and listens to concerns.  
Two days later, the psychiatric nurse specialist (PNS) assesses that Mr. O continued to 
eat and drink well, his UA was negative, and his behaviors continued to escalate. She notes, his 
significant sleep disorder is affecting his quality of life. When staff nurses come to assist him, he 
strikes out at them, and yells at them to “get out of here”, and when the staff explain to him that 
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they must help him with his self-releasing belt alarm, he strikes out at them in rage. The PNS 
finds Mr. O is oriented to him self only, and observes his inability to join activities because of his 
severe irritability and short attention span. She notes he is distrustful of staff, easily distracted, 
with impaired judgment, insight, memory, and impulse control. Mr. O is hyper-vigilant and 
combative to direct care staff, putting him and others at risk for injury. The PNS interviews the 
family and administers a proxy informant Quality of Life-AD scale that revealed a low score 
based on Mr. O’s energy level, mood, memory, recent loss of spouse, change in residence, and 
death of several close friends in the past year. The family believes Mr. O’s QoL is poor because 
of his inability to read his Bible, watch TV, or listen to gospel music that he used to enjoy. They 
are sad by his cursing and shouting because they remember him as a calm and proper man before 
he developed AD. Per consultation with a gero-psychiatrist and in collaboration with the 
physician, NP and family, a recommendation to taper off quetiapine and start olanzapine 5 mg 
orally every night for 5 nights then increase olanzapine to 10 mg orally every night with 
depakote sprinkles 250 mg orally daily.  
A complete discussion of possible benefits and risks including increased risk of stroke or 
death was conducted, and consent forms were signed by the DPOA. The diagnosis for 
antipsychotic use is AD with delusional disorder with behaviors that risk harm to self or others. 
The target symptoms are hours of sleep, mood and verbal and physical aggression. A monitoring 
system was created on the nurse’s medication administration record to document frequency of 
symptoms per shift and hours of sleep. The sertraline was continued for depression, and 
donepezil was continued, with a possible dose increase later for maximum effect on behavior. 
Advise was given to nursing to continue fall risk precautions and continue 1:1 care giving which 
the family provides 4 hours per day.  
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The goals of care were defined within a palliative care model to improve quality of life 
and reduce distress from debilitating symptoms. The family agreed to hospice care once Mr. O 
became more bedbound, less verbal, developed eating or swallowing problems, or developed an 
acute illness or infection. The family wanted to avoid future hospitalizations that did not address 
the underlying disease trajectory and the terminal nature of advanced dementia. Several days 
later the PNS assessed Mr. O and documented that he continued to eat and drink well and take 
his medicines but remained hyper-vigilant and combative to direct care staff. She implemented a 
Cohen-Mansfield Agitation Inventory (CMAI) short form, and Mr. O’s score was 45, which is a 
measure of symptom frequency. In collaboration with the gero-psychiatrist, a recommendation to 
increase the olanzapine to 15 mg at night and increase the depakote sprinkles to 250 mg twice 
daily with a CBC, ALT, and drug level in one week to monitor for a possible adverse drug 
reaction. The family agreed to the plan, and the DPOA signed another consent to increase the 
dose of the medications as recommended. The physician and NP were consulted and 
implemented the medication changes, and lab orders.  
A week and a half later, the NP noticed Mr. O was enjoying more time outside, 
occasional chaplain visits, and was able to listen to his grandson read the Bible to him. The NP 
checked the follow-up labs and completed another CAMI short form and Mr. O’s score was 18, 
showing a significant improvement. This was reported to the gero-psych team and the nursing 
home IDT who projected in 4 weeks, a re-evaluation of the medical regimen would be possible, 
and a dose reduction may be considered if symptom management remained stable. The family 
returned a quarterly satisfaction survey as a quality outcome measure of their approval of the 
care delivery. The physician and NP continue to monitor for efficacy and tolerability of 
medications on routine medical rounds and update the documentation on the Psychotropic Risk 
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Assessment Checklist quarterly. Discussions with the patient’s family or proxy at that time 
review the benefits versus the risks of psychotropic medications, and consider trial dose 
reductions to lower the risk burden if the patient’s perceived QoL benefit can be maintained or 
improved.  
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Gap Analysis 
A gap analysis is based on the knowledge that current clinical care for patients with 
advanced dementia, complicated by the behavioral disturbances of BPSD, is often fragmented 
and disease oriented, rather than person-centered in long term care. There were no known pre-
existing tools to assist clinicians to formulate risk/benefit analysis with psychotropic use.  
Incorporating palliative care components such as end of life care, quality of life (QoL) concepts, 
and shared decision-making for BPSD management, is not new, but has not been readily applied 
to the critical thinking with psychotropic use. Many care delivery strategies and non-
pharmacological interventions are inconsistently applied or undocumented. There has been a 
void between palliative care and QoL measures for individuals with advanced dementia who are 
near the end of life. This project implementation was an early attempt to weigh the benefits 
against the risks of psychotropic medications for those with BPSD, and blend palliative care with 
advanced dementia care, with a focus on QoL outcomes. 
 
 
 
 
